Split 9th Circuit Reinstates FCA Claims As To Regeneron, Affirms Sanofi Dismissal
SAN FRANCISCO — A split Ninth Circuit U.S. Court of Appeals on Aug. 19 found that a lower court erred in dismissing False Claims Act (FCA) claims against Regeneron Pharmaceuticals Inc....To view the full article, register now.
Already a subscriber? Click here to view full article